Generic drugmaker and biotech company Laurus Labs reported consolidated net profit for June quarter surged to ₹163 crore from ₹13 crore year earlier.
The higher net profit came on a 31% increase in revenue from operations to ₹1,570 crore (₹1,195 crore). Founder and CEO Satyanarayana Chava attributed the performance to increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF.
The company’s shares registered a new 52-week high of ₹845.60 each on Friday (July 25, 2025) before closing less than 1% higher at ₹838.85 apiece on the BSE.
“We are moving ahead with strong focus on commercial execution realising the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities. Construction of various facilities across CDMO, generics and FDF has commenced,” he said.
Revenue breakup showed share of CDMO went up to ₹522 crore (₹257 crore), while contribution of generics increased 12% to ₹1,048 crore (₹938 crore). The company said CDMO growth was driven by several mid-to-late stage NCE deliveries and ramp up from new manufacturing assets. There was sustained demand in high-value and complex small molecule offerings. Bio business reported lower revenue at ₹29 crore (₹43 crore) on impact by customer specific scale-up and scheduling issue. Generics revenue growth was driven by both ARV and developed market portfolio within FDF, Laurus Labs said.
Published – July 25, 2025 06:47 pm IST
